Government's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for key raw materials like penicillin G, industry executives report a lack of clear beneficial impact. Buyers and manufacturers are hesitant to shift to domestic suppliers at MIP-linked prices, leaving significant production capacity underutilized. Some anticipate this is a temporary phase as existing stockpiles are consumed.
RSS News
Economic times
0 thoughts on “Drugmakers yet to see gains from government's minimum import price policy”
Leave a Reply
Your email address will not be published. Required fields are marked *
RECENT NEWS
- IND vs ENG: All eyes will be on these 3 players in the second T20I, one is in danger of being ruled out
- Carl Benedict Frey's column: We don't do any work just for income
- Shivya Nath's column: Harmony of life should be learned from the children of the forest
- Inside India’s language conundrum
- IND vs ENG: India vs England 2nd T20 Match Interrupted Due to Rain
